Nanni Cristina, Cottereau Anne Ségolène, Lopci Egesta, Bodet-Milin Caroline, Coronado Monica, Pro Barbara, Kim Wong Seog, Trotman Judith, Barrington Sally, Duhrsen Ulrich, Vander Borght Thierry, Zamagni Elena, Kraeber-Bodéré Françoise, Messiou Christina, Rahmouni Alain, Buvat Irène, Andre Marc, Hertzberg Mark, Oyen Wim, Casasnovas Olivier, Luminari Stefano, Garderet Laurent, Montravers Françoise, Kobe Carsten, Kluge Regine, Versari Annibale, Zucca Emanuele, Moreau Philippe, Cheson Bruce, Haioun Corinne, Gallamini Andrea, Meignan Michel
a Nuclear Medicine and Hematology , University of Bologna , Bologna , Italy.
b Nuclear Medicine , Hôpital Tenon , Paris , France.
Leuk Lymphoma. 2017 Oct;58(10):2298-2303. doi: 10.1080/10428194.2017.1298752. Epub 2017 Mar 7.
Two hundred and ten nuclear medicine physicians, radiologists, and hematologists from 26 countries attended the 6th International Workshop on Positron Emission Tomography (PET) in Lymphoma and Myeloma held in Menton, France, in September 2016. The meeting was under the auspices of the European Lymphoma Institute (ELI), the European Association of Nuclear Medicine (EANM) the Lymphoma Study Association (LYSA), the Italian Foundation on Lymphoma (FIL) and the Carnot Institute for Lymphoma (CALYM). Forty scientific posters were presented. For the first time, specialists in the field of multiple myeloma (MM) were involved in the expert session. The aim was to establish from the experience of Italian and French studies new guidelines of FDG-PET/CT reporting for myeloma staging and restaging. The meeting dedicated an entire session to MM imaging followed by a session on the role of PET in Peripheral T cell Lymphoma. An entire session addressed the issues of Deauville scale particularly for end treatment assessment and the challenging consequences of immunomodulatory treatments on PET reporting. A specific session presented the potential role of baseline metabolic tumor measurement to predict outcome and identify different risk categories and the main results obtained in different lymphoma entities were described. Whether it could replace clinical staging has been extensively discussed. The more recent results obtained in the H10 trial have been presented and compared to the published data in early stage Hodgkin lymphoma. Finally, the ongoing studies using PET for guiding therapeutic strategies have been reported by the various lymphoma cooperative groups that participated to the meeting.
2016年9月，来自26个国家的210名核医学医师、放射科医生和血液科医生参加了在法国芒通举行的第六届淋巴瘤和骨髓瘤正电子发射断层扫描（PET）国际研讨会。该会议由欧洲淋巴瘤研究所（ELI）、欧洲核医学协会（EANM）、淋巴瘤研究协会（LYSA）、意大利淋巴瘤基金会（FIL）和卡诺淋巴瘤研究所（CALYM）主办。会上展示了40篇科学海报。骨髓瘤（MM）领域的专家首次参与了专家会议。目的是根据意大利和法国的研究经验，制定用于骨髓瘤分期和再分期的FDG-PET/CT报告新指南。会议专门安排了一场关于MM成像的全会，随后是一场关于PET在周围T细胞淋巴瘤中的作用的会议。一场全会专门讨论了多维尔量表的问题，特别是用于最终治疗评估以及免疫调节治疗对PET报告的挑战性影响。一场特定的会议介绍了基线代谢肿瘤测量在预测预后和识别不同风险类别方面的潜在作用，并描述了在不同淋巴瘤实体中获得的主要结果。它是否可以取代临床分期已得到广泛讨论。会上展示了H10试验中获得的最新结果，并与早期霍奇金淋巴瘤的已发表数据进行了比较。最后，参加会议的各个淋巴瘤合作组报告了正在进行的使用PET指导治疗策略的研究。
